

***XRCC3* and *XPB/ERCC2* single nucleotide polymorphisms and the risk of cancer: A HuGE review**

Web Material

References to the tables in alphabetical order

Allan JM, Smith AG, Wheatley K, et al. Genetic variation in *XPB* predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. *Blood* 2004;104(13):3872-7

Benhamou S, Tuimala J, Bouchardy C, et al. DNA repair gene *XRCC2* and *XRCC3* polymorphisms and susceptibility to cancers of the upper aerodigestive tract. *Int J Cancer* 2004;112(5):901-4.

Bertram CG, Gaut RM, Barrett JH, et al. An assessment of a variant of the DNA repair gene *XRCC3* as a possible nevus or melanoma susceptibility genotype. *J Invest Dermatol* 2004;122(2):429-32.

Brewster AM, Alberg AJ, Strickland PT, et al. *XPB* polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13(8):1271-5.

Butkiewicz D, Rusin M, Enewold L, et al. Molecular epidemiology and cancer prevention ? Genetic polymorphisms in DNA repair genes and risk of lung cancer. *Carcinogenesis* 2001; 22: 593-597

Caggana M, Kilgallen J, Conroy JM, et al. Associations between *ERCC2* polymorphisms and gliomas. *Cancer Epidemiol Biomarkers Prev* 2001;10:355-60.

Chen S, Tang D, Xue K, et al. DNA repair gene *XRCC1* and *XPB* polymorphisms and risk of lung cancer in a Chinese population. *Carcinogenesis* 2002 Aug;23(8):1321-5.

David-Beabes GL, Lunn RM, London SJ. No association between the *XPB* (Lys751Gln) polymorphism or the *XRCC3* (Thr241Met) polymorphism and lung cancer risk. *Cancer Epidemiol Biomarkers Prev* 2001;10(8):911-2.

Duan Z, Shen H, Lee JE, et al. DNA repair gene *XRCC3* 241Met variant is not associated with risk of cutaneous malignant melanoma. *Cancer Epidemiol Biomarkers Prev*. 2002;11(10 Pt 1):1142-3.

Dybdahl M, Vogel U, Frentz G, et al. Polymorphisms in the DNA repair gene *XPB*: correlations with risk and age at onset of basal cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 1999;8:77-81

Figueiredo JC, Knight JA, Briollais L, et al. Polymorphisms *XRCC1*-R399Q and *XRCC3*-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. *Cancer Epidemiol Biomarkers Prev* 2004;13(4):583-91

Gao WM, Romkes M, Day RD, et al. Association of the DNA repair gene *XPB* Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. *Carcinogenesis*. 2003;24(10):1671-6.

Han J, Hankinson SE, Ranu H, et al. Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. *Carcinogenesis* 2004a;25(2):189-95.

Han J, Colditz GA, Samson LD, et al. Polymorphisms in DNA double-strand break repair genes and skin cancer risk. *Cancer Res* 2004b;64(9):3009-13.

Han J, Hankinson SE, Hunter DJ, et al. Genetic variations in *XRCC2* and *XRCC3* are not associated with endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev* 2004c;13(2):330-1.

Harms C, Salama SA, Sierra-Torres CH, et al. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. *Environ Mol Mutagen* 2004;44(1):74-82.

Hou SM, Falt S, Angelini S, et al. The *XPB* variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. *Carcinogenesis* 2002;23(4):599-603.

Jacobsen NR, Nexø BA, Olsen A, et al. No association between the DNA repair gene *XRCC3* T241M polymorphism and risk of skin cancer and breast cancer. *Cancer Epidemiol Biomarkers Prev* 2003;12(6):584-5.

Jacobsen NR, Raaschou-Nielsen O, Nexø B, et al. *XRCC3* polymorphisms and risk of lung cancer. *Cancer Lett*. 2004;213(1):67-72.

Justenhoven C, Hamann U, Pesch B, et al. *ERCC2* genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. *Cancer Epidemiol Biomarkers Prev* 2004;13(12):2059-64.

Liang G, Xing D, Miao X, et al. Sequence variations in the DNA repair gene *XPB* and risk of lung cancer in a Chinese population. *Int J Cancer* 2003;105(5):669-73.

Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. *Int J Cancer* 2001; 92: 562-567

Medina PP, Ahrendt SA, Pollan M, et al. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. *Cancer Epidemiol Biomarkers Prev* 2003;12(8):699-704

Misra RR, Ratnasinghe D, Tangrea JA, et al. Polymorphisms in the DNA repair genes *XPB*, *XRCC1*, *XRCC3*, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. *Cancer Lett* 2003;191(2):171-8.

Park JY, Lee SY, Jeon HS, et al. No abstract Lys751Gln polymorphism in the DNA repair gene *XPB* and risk of primary lung cancer. *Lung Cancer* 2002;36(1):15-6.

Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. *Carcinogenesis*. 2004;25(12):2433-41.

Rybicki BA, Conti DV, Moreira A, et al. DNA repair gene *XRCC1* and *XPB* polymorphisms and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2004;13(1):23-9.

Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. *Carcinogenesis*. 2004;25(5):729-34.

Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the *XRCC1* gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. *Blood*. 2002;100(10):3761-6

Shen H, Sturgis EM, Dahlstrom KR, et al. A variant of the DNA repair gene *XRCC3* and risk of squamous cell carcinoma of the head and neck: a case-control analysis. *Int J Cancer*. 2002;99(6):869-72.

Shen H, Wang X, Hu Z, et al. Polymorphisms of DNA repair gene *XRCC3* Thr241Met and risk of gastric cancer in a Chinese population. *Cancer Lett*. 2004;206(1):51-8.

Shen M, Hung RJ, Brennan P, et al. Polymorphisms of the DNA repair genes *XRCC1*, *XRCC3*, *XPB*, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. *Cancer Epidemiol Biomarkers Prev* 2003;12(11 Pt 1):1234-40.

Shi Q, Wang LE, Bondy ML, et al. Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common *XPB* polymorphisms in breast cancer patients. *Carcinogenesis* 2004;25(9):1695-700.

Smith TR, Miller MS, Lohman K, et al. Polymorphisms of *XRCC1* and *XRCC3* genes and susceptibility to breast cancer. *Cancer Lett* 2003a;190(2):183-90.

Smith TR, Levine EA, Perrier ND, et al. DNA-repair genetic polymorphisms and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003b;12(11 Pt 1):1200-4

Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by *XPB* polymorphisms in lung cancer patients. *Cancer Res* 2001 61, 1354-1357

Stern MC, Johnson LR, Bell DA, et al. Abstract *XPB* codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002a;11(10 Pt 1):1004-11.

Stern MC, Umbach DM, Lunn RM, et al. DNA repair gene *XRCC3* codon 241 polymorphism, its interaction with smoking and *XRCC1* polymorphisms, and bladder cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002b;11(9):939-43.

Sturgis EM, Castillo EJ, Li L, et al. *XPB/ERCC2* EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. *Oral Oncol* 2002;38(5):475-7.

Sturgis EM, Zheng R, Li L, et al. *XPB/ERCC2* polymorphism and risk of head and neck cancer: a case-control analysis. *Carcinogenesis* 2000; 21:2219-2223

Tang D, Cho S, Rundle A, et al. Polymorphisms in the DNA repair enzyme *XPB* are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. *Breast Cancer Res Treat* 2002;75(2):159-66.

Terry MB, Gammon MD, Zhang FF, et al. Polymorphism in the DNA repair gene *XPB*, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2004;13(12):2053-8.

Tomescu D, Kavanagh G, Ha T, et al. Nucleotide excision repair gene *XPB* polymorphisms and genetic predisposition to melanoma. *Carcinogenesis* 2001; 3: 403-8

Vogel U, Hedayati M, Dybdahl M, et al. Molecular epidemiology and cancer prevention ? Polymorphisms of the DNA repair gene *XPB*: correlations with risk of basal cell carcinoma revisited. *Carcinogenesis* 2001;22: 899-904

Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. *Cancer Res* 2004;64(16):5560-3.

Wang Y, Liang D, Spitz MR, et al. *XRCC3* genetic polymorphism, smoking, and lung carcinoma risk in minority populations. *Cancer* 2003;98(8):1701-6.

Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene *XRCC3* is associated with the development of melanoma skin cancer. *Cancer Res* 2000; 60 : 612-616

Xing D, Qi J, Miao X, et al. Polymorphisms of DNA repair genes *XRCC1* and *XPB* and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. *Int J Cancer* 2002a;100(5):600-5.

Xing D, Tan W, Wei Q, et al. Polymorphisms of the DNA repair gene *XPB* and risk of lung cancer in a Chinese population. *Lung Cancer* 2002b;38(2):123-9.

Yeh CC, Sung FC, Tang R, et al. Polymorphisms of the *XRCC1*, *XRCC3*, & *XPB* genes, and colorectal cancer risk: A case-control study in Taiwan. *BMC Cancer*. 2005;5(1):12

Yin J, Rockenbauer E, Hedayati M, et al. Multiple single nucleotide polymorphisms on human chromosome 19q13.2-3 associate with risk of Basal cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2002;11(11):1449-53.

Yu HP, Wang XL, Sun X, et al. Polymorphisms in the DNA repair gene *XPB* and susceptibility to esophageal squamous cell carcinoma. *Cancer Genet Cytogenet* 2004;154(1):10-5.

Zhou W, Liu G, Miller DP, et al. Gene-environment interaction for the *ERCC2* polymorphisms and cumulative cigarette smoking exposure in lung cancer. *Cancer Res* 2002;62(5):1377-81.

Table 1 Genotype and allele frequencies.

XRCC3-IVS6 1571

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	Hardy-Weinberg p
			T	C	TT	TC	CC		
Jacobsen	2004	Caucasians	92.6	7.4	85.9	13.4	0.7	269	0.715

XRCC3-IVS5-14

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			A	G	AA	AG	GG		
Jacobsen	2004	Caucasians	63.7	36.3	40.1	47.2	12.7	269	0.735
Han	2004c	Mixed	64.1	36.0	41.6	44.9	13.5	659	0.521
Han	2004a	Undefined	69.5	30.5	48.0	43.0	9.0	1265	0.612

XRCC3-Cod.241

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			C (Thr)	T (Met)	CC	CT	TT		
David-Beabes	2001	African-Americans	76.9	23.1	58.1	37.6	4.3	234	0.372
Wang	2003	African-Americans	78.0	22.0	62.6	30.8	6.6	91	0.327
		African-Americans			59.1	35.4	4.6	325	
Shen	2004	Asians	95.3	4.9	90.4	9.7	0.0	166	0.500
Yeh	2005	Asians	94.8	5.4	89.7	10.1	0.3	736	0.855
		Asians			89.8	10.0	0.2	902	
Winsey	2000	Caucasians	70.5	29.5	52.0	37.0	11.0	211	0.109
Matullo	2001	Caucasians	63.0	37.0	49.0	28.0	23.0	85	<0.001
David-Beabes	2001	Caucasians	61.8	38.2	38.6	46.4	15.0	453	0.713
Seedhouse	2002	Caucasians	70.9	29.2	52.6	36.6	10.9	175	0.127
Duan	2002	Caucasians	61.2	38.9	36.4	49.5	14.1	319	0.455
Shen	2002	Caucasians	63.8	36.2	39.8	48.0	12.2	354	0.461
Jacobsen	2003	Caucasians	66.8	34.2	46.3	41.0	13.7	315	0.081
Jacobsen	2003	Caucasians	61.4	38.9	37.9	46.9	15.4	422	0.761
Misra	2003	Caucasians	71.0	29.0	49.0	44.0	7.0	315	0.224
Bertram	2004	Caucasians	64.0	36.0	40.0	48.0	12.0	335	0.446
Shen	2003	Caucasians	60.0	40.0	33.0	54.0	13.0	214	0.067
Sanyal	2004	Caucasians	66.0	34.0	44.0	44.0	12.0	246	0.758
Harms	2004	Caucasians	71.5	28.5	51.0	41.0	8.0	119	0.948
Wang	2004	Caucasians	64.5	35.5	43.0	43.0	14.0	342	0.259
Benhamou	2004	Caucasians	55.1	44.9	28.3	53.6	18.1	166	0.283

Jacobsen	2004	Caucasians	63.0	37.0	42.0	42.0	16.0	269	0.104
Smith	2003	Caucasians	62.8	35.3	38.7	48.1	11.2	268	0.218
		Caucasians			41.4	44.9	12.4	4608	
Wang	2003	Hispanic	77.8	22.2	62.6	30.3	7.1	99	0.220
Stern	2002	Mixed	67.0	33.0	45.0	44.0	11.0	209	0.943
David-Beabes	2001	Mixed	67.0	33.1	45.3	43.4	11.4	687	0.587
Smith	2003	Mixed	60.5	39.6	37.1	46.7	16.2	302	0.685
Wang	2003	Mixed	81.3	18.7	62.6	37.4	0.0	190	0.002
Han	2004b	Mixed	61.5	38.6	37.0	48.9	14.1	810	0.361
Han	2004c	Mixed	65.1	34.9	42.1	46.0	11.9	665	0.751
Han	2004a	Undefined	62.5	37.5	38.0	49.0	13.0	1245	0.110
Popanda	2004	Undefined	61.0	39.0	37.0	48.0	15.0	460	0.850
Figueiredo	2004	Undefined	61.2	38.8	36.3	49.8	13.9	402	0.330

XRCC3-A4552C

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			A	C	AA	AC	CC		
Han	2004	Mixed	81.0	19.1	65.5	30.9	3.6	861	0.956

XRCC3-5' region pos.4541

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			A	G	AA	AG	GG		
Winsey	2000	Caucasians	23.0	77.0	4.0	38.0	58.0	211	0.290
Jacobsen	2004	Caucasians	80.9	18.2	66.8	28.1	4.1	268	0.334
		Caucasians			39.0	32.4	27.6	479	
Han	2004c	Mixed	81.2	18.9	66.1	30.1	3.8	663	0.678
Han	2004a	Undefined	79.5	20.5	67.0	25.0	8.0	1291	<<0.001

XPB/ERCC2-Intron 4

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			A	G	AA	AG	GG		
Yin	2002	Caucasians	40.2	59.8	20.6	39.2	40.2	97	0.069

XPB/ERCC2-Cod.751

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			C (Gln)	A (Lys)	CC	CA	AA		
David-Beabes	2001	African-Americans	25.1	75.1	5.6	38.9	55.6	234	0.586

Stern	2002a	African -Americans	65.0	35.0	38.0	54.0	8.0	13	0.501
		African -Americans			6.9	39.7	53.0	247	
Park	2002	Asians	5.5	94.5	0.0	11.0	89.0	163	0.457
Xing	2002	Asians	7.3	92.8	0.6	13.3	86.1	524	0.800
Liang	2003	Asians	8.7	91.3	0.6	16.3	83.1	1010	0.494
Chen	2002	Asians	40.4	59.7	18.3	44.1	37.6	109	0.381
Xing	2002	Asians	7.2	92.8	0.8	12.8	86.4	383	0.409
Yu	2004	Asians	6.9	93.1	1.3	11.2	87.5	152	0.114
Yeh	2005	Asians	7.2	92.9	0.6	13.1	86.3	736	0.717
		Asians			1.1	14.9	83.6	3077	
Sturgis	2000	Caucasians	33.8	66.3	11.5	44.5	44.0	496	0.913
Dybdahl	1999	Caucasians	40.0	60.0	20.0	40.0	40.0	20	0.456
Winsey	2000	Caucasians	40.5	59.5	15.0	51.0	34.0	211	0.398
Spitz	2001	Caucasians	33.3	66.7	10.8	45.0	44.2	360	0.805
Vogel	2001	Caucasians	36.4	63.7	10.3	52.1	37.6	117	0.173
Matullo	2001	Caucasians	45.5	54.5	17.0	57.0	26.0	85	0.169
Caggana	2001	Caucasians	41.5	58.5	16.0	51.0	33.0	148	0.540
Stern	2002a	Caucasians	37.5	62.5	15.0	45.0	40.0	197	0.575
David-Beabes	2001	Caucasians	34.7	65.3	12.8	43.7	43.5	453	0.458
Seedhouse	2002	Caucasians	37.0	63.0	15.1	43.8	41.1	73	0.605
Misra	2003	Caucasians	40.5	59.5	15.0	51.0	34.0	315	0.302
Rybicki	2004	Caucasians	35.6	64.5	12.0	47.1	40.9	437	0.560
Shen	2003	Caucasians	40.0	60.0	17.0	46.0	37.0	214	0.542
Baccarelli	2004	Caucasians	42.7	57.3	18.7	48.0	33.3	177	0.800
Sanyal	2004	Caucasians	38.0	62.0	15.0	46.0	39.0	246	0.709
Harms	2004	Caucasians	27.5	72.5	6.0	43.0	51.0	119	0.393
Shi	2004	Caucasians	29.8	70.3	7.6	44.3	48.1	79	0.595
Allan	2004	Caucasians	36.5	63.5	15.0	43.0	42.0	729	0.051
Zhou	2002	Caucasians	36.0	63.0	13.0	46.0	40.0	1240	0.595
Justenhoven	2004	Caucasians	36.5	63.5	14.0	45.0	41.0	643	0.459
		Caucasians			13.4	45.8	40.1	6359	
David-Beabes	2001	Mixed	31.4	68.7	10.3	42.1	47.6	687	0.566
Buch	2005	Mixed	27.5	72.5	11.9	31.2	56.9	269	<0.001
Tang	2002	Undefined	36.4	63.6	17.4	38.0	44.6	121	0.049
Allan	2004	Undefined	36.5	63.5	15.0	43.0	42.0	729	0.051
Popanda	2004	Undefined	36.5	63.5	14.0	45.0	41.0	460	0.531
Terry	2005	Undefined	36.3	63.7	13.7	45.2	41.1	1102	0.453

XPD/ERCC2-Cod.711

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N
			C (Asp)	T (Asp)	CC	CT	TT	

Caggana	2001	Caucasians	67.0	32.0	46.0	42.0	11.0	140	0.658
---------	------	------------	------	------	------	------	------	-----	-------

XPD/ERCC2-Cod.312

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			G (Asp)	A (Asn)	GG	GA	AA		
Xing	2002	Asians	93.9	6.1	88.0	11.8	0.2	524	0.492
Liang	2003	Asians	93.5	6.5	87.2	12.8	0.1	1020	0.083
Xing	2002	Asians	94.2	5.9	88.3	11.7	0.0	383	0.224
Yu	2004	Asians	94.8	5.3	89.5	10.5	0.0	152	0.495
		Asians			87.7	12.0	0.0	2079	
Winsey	2000	Caucasians	64.5	35.5	42.0	45.0	13.0	211	0.801
Spitz	2001	Caucasians	72.8	27.3	52.5	40.5	7.0	360	0.684
Butkiewicz	2001	Caucasians	56.5	43.5	31.0	51.0	18.0	96	0.713
Vogel	2001	Caucasians	62.4	37.7	43.8	37.1	19.1	105	0.032
Caggana	2001	Caucasians	64.5	35.5	41.0	47.0	12.0	137	0.758
Misra	2003	Caucasians	63.5	36.5	40.0	47.0	13.0	315	0.805
Rybicki	2004	Caucasians	66.2	33.9	41.2	49.9	8.9	437	0.017
Baccarelli	2004	Caucasians	60.2	39.9	34.3	51.7	14.0	172	0.304
Shi	2004	Caucasians	75.3	24.7	58.2	34.2	7.6	79	0.474
Zhou	2002	Caucasians	67.0	33.0	44.0	46.0	10.0	1240	0.156
Justenhoven	2004	Caucasians	66.0	34.0	45.0	42.0	13.0	610	0.113
		Caucasians			43.5	45.1	11.1	3762	
Tang	2002	Undefined	78.6	21.4	66.1	25.0	8.9	112	0.007
Popanda	2004	Undefined	63.5	36.5	42.0	43.0	15.0	460	0.121

XPD/ERCC2-Cod.156

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			C (Arg)	A (Arg)	CC	CA	AA		
Sturgis	2000	Caucasians	55.4	44.7	31.1	48.6	20.4	496	0.691
Dybdahl	1999	Caucasians	62.5	37.5	40.0	45.0	15.0	20	0.858
Winsey	2000	Caucasians	60.0	40.0	33.0	54.0	13.0	211	0.069
Vogel	2001	Caucasians	59.0	41.0	37.8	42.3	19.8	111	0.189
Caggana	2001	Caucasians	61.5	38.5	40.0	43.0	17.0	139	0.278
		Caucasians			33.5	47.9	17.9	977	

XPD/ERCC2-201

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N
			C (His)	T (Tyr)	CC	CT	TT	
Sturgis	2002	Caucasians	100.0	0.0	100.0	0.0	0.0	400

XPD/ERCC2-199

Study	Year	Ethnicity	Allele Freq (%)		Genotype Frequency (%)			N	
			C (Ile)	G (Met)	CC	CG	GG		
Sturgis	2002	Caucasians	99.2	0.9	98.3	1.7	0.0	400	0.864

Table 2. Study design: *XPD/ERCC2*

Study	Date	Nationality	Polymorphisms	Cancer Site	Method	Design	Ethnic group	No. case-controls	Exposure
Dybdahl	1999	Denmark	<i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.156	Skin	PCR-RFLP	H-B casecontrol	Caucasian	40/40	NULL
Sturgis	2000	USA	<i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.156	Head and neck	PCR-RFLP	H-B case-control	Non-Hispanic whites	189/496	Smoking, alcohol
Winsey	2000	UK	<i>XRCC1</i> Cod.399 <i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.156 <i>XRCC1</i> Cod.194 <i>XPD/ERCC2</i> Cod.312 <i>XPF/ERCC4</i> 5' UTR pos.2063 <i>XPF/ERCC4</i> Exon 11 pos.30028 <i>ERCC1</i> Exon 4 pos.19007 <i>XRCC3</i> Cod.241 <i>XRCC3</i> 5' region pos.4541	Skin	PCR-SSCP	H-B case control	Caucasians	125/211	NULL
Butkiewicz	2001	Poland	<i>XPD/ERCC2</i> Cod.312	Lung	PCR-RFLP	P-B case-control	Whites	96/96+52 members of 4 families	Smoking NULL
Caggana	2001	USA	<i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.156 <i>XPD/ERCC2</i> Cod.312 <i>XPD/ERCC2</i> Cod.711	Glioma	PCR-RFLP	P-B case control	Caucasian and Others	187/169	NULL
David-Beabes	2001	USA	<i>XPD/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Lung	PCR-RFLP	P-B case-control	Caucasians African Americans	331/687	NULL
Matullo	2001	Italy	<i>XRCC1</i> Cod.399 <i>XPD/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Bladder	PCR-RFLP	H-B case-control	Caucasians	124/85	Smoking
Spitz	2001	USA	<i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.312	Lung	PCR-RFLP HCRA	H-B case-control	Whites	341/360	Smoking,alcohol
Tomescu	2001	Scotland	<i>XPD/ERCC2</i> Cod.751 <i>XPD/ERCC2</i> Cod.156 <i>ERCC1</i> Exon 4 pos.19007 <i>XPD/ERCC2</i> Cod.711 <i>CKM</i> Exon 8 <i>CKM</i> 3'	Skin	PCR-RFLP	H-B case-control	Caucasians	28/28	NULL

Vogel	2001	USA	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.156 <i>XPB/ERCC2</i> Cod.312	Skin	PCR-RFLP	H-B case-control	Caucasians	70/117	Sunburns, skin type
Chen	2002	USA China	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC1</i> Cod.194	Lung	PCR-RFLP	P-B case control	Asians	109/109	Smoking
Hou	2002	Sweden	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Lung	PCR-RFLP	P-B case control	Undefined	185/162	Smoking
Park	2002	South Korea	<i>XPB/ERCC2</i> Cod.751	Lung	PCR-RFLP	H-B case-control	Asians	250/163	Smoking
Seedhouse	2002	UK	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC1</i> Cod.194 <i>XRCC3</i> Cod.241 <i>NQO1</i> Cod. 187	Leukemia Secondary leukemia	PCR-RFLP	H-B case control	Caucasians	168/178	NULL
Stern	2002a	USA	<i>XPB/ERCC2</i> Cod.751	Bladder	PCR-RFLP	H-B case-control	Whites and blacks	228/210	Smoking
Sturgis	2002	USA	<i>XPB/ERCC2</i> 23047 <i>XPB/ERCC2</i> 23051	Head and neck	PCR-RFLP	H-B case control	Non-Hispanic whites	180/400	NULL
Tang	2002	USA	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Breast	PCR-RFLP	H-B case control	Undefined	103/215	NULL
Xing	2002a	China	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC1</i> Cod.194 <i>XPB/ERCC2</i> Cod.312	Esophageal	PCR-RFLP	P-B case control	Asians	433/524	Smoking
Xing	2002b	China	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Lung	PCR-RFLP	P-B case control	Asians	351/383	Smoking
Yin	2002	Denmark	<i>XRCC1</i> Cod.399 <i>ERCC1</i> Exon 4 pos.19007 <i>CKM</i> Exon 8 <i>LIG1</i> exon 6 <i>XPB/ERCC2</i> Intron 4 <i>RAI</i> Exon 6 <i>RAI</i> Intron 1 <i>FOSB</i> Exon 4 <i>SLC1A5</i> Exon 8 <i>GLTSCR1</i> Exon 1	Skin	TaqMan	H-B case control	Caucasians	97/58	NULL
Zhou	2002	USA	<i>XPB/ERCC2</i> Cod.751	Lung	PCR-RFLP	P-B case control	Caucasians	1092/1240	Smoking

			<i>XPB/ERCC2</i> Cod.312						
Gao	2003	USA	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Lung	TaqMan	Case-Only	Caucasians	204	Smoking
Liang	2003	China	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Lung	PCR-RFLP	P-B case control	Asians	1006/1020	Smoking
Misra	2003	Finland	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312 <i>XRCC3</i> Cod.241 <i>XRCC1</i> Cod.280 <i>APEX</i> Cod. 148	Lung	TaqMan	P-B case control	Caucasians	315/315	Smoking
Shen	2003	USA Italy	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Bladder	PCR-RFLP	H-B case control	Caucasians	201/214	Smoking
Allan	2004	UK	<i>XPB/ERCC2</i> Cod.751	Leukemia	PCR-RFLP	P-B case control	Undefined	852/729	NULL
Baccarelli	2004	USA Italy	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Skin	TaqMan	P-B case control	Caucasians	176/177	Sunlight
Brewster	2004	USA	<i>XPB/ERCC2</i> Cod.751	Skin	TaqMan	Case-cohort	Undefined	80/401	Smoking
Harms	2004	USA	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Lung	PCR-RFLP	H-B case control	Caucasians	110/119	Smoking
Justenhoven	2004	Germany	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Breast	Sequencing	P-B case control	Caucasians	688/724	Smoking
Popanda	2004	Germany	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312 <i>XRCC3</i> Cod.241 <i>XPA</i> 5' NCR <i>APEX</i> Cod. 148	Lung	PCR-RFLP	H-B case control	Caucasians	463/460	Smoking
Rybicki	2004	USA	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Prostate	PCR-RFLP	P-B case control	Caucasians	637/480	NULL
Sanyal	2004	Sweden	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Bladder	TaqMan PCR-RFLP	H-B case control	Caucasians	327/246	NULL

			<i>CCND1</i> Cod.870 <i>XPG</i> Cod. 1104 <i>NQO1</i> Exon 6 <i>NBS1</i> Cod. 185 <i>XPC</i> exon 4 <i>MTHFR</i> exon 4 <i>MTHFR</i> exon 7 <i>NQO1</i> exon 4 <i>H-ras</i> exon 1 <i>GSTT1</i> Deletion allele						
Shi	2004	USA	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Breast	PCR-RFLP	H-B case control	Non-Hispanic whites	69/79	Smoking
Yu	2004	China	<i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312	Esophageal	PCR-RFLP	H-B case control	Asians	135/152	Smoking Alcohol
Terry	2005	USA	<i>XPB/ERCC2</i> Cod.751	Breast	Other	P-B case control	Undefined	1053/1102	Smoking
Yeh	2005	Taiwan	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Colorectal	PCR-RFLP	H-B case control	Asians	727/736	NULL

Table 3. Study design: *XRCC3*

Study	Date	Nationality	Polymorphisms	Cancer Site	Method	Design	Ethnic group	Num. case-controls	Exposures
Winsey	2000	UK	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.156 <i>XRCC1</i> Cod.194 <i>XPB/ERCC2</i> Cod.312 <i>XPB/ERCC4</i> 5' UTR pos.2063 <i>XPB/ERCC4</i> Exon 11 pos.30028 <i>ERCC1</i> Exon 4 pos.19007 <i>XRCC3</i> Cod.241 <i>XRCC3</i> 5' region pos.4541	Skin	PCR-SSCP	H-B case control	Caucasians	125/211	NULL
David-Beabes	2001	USA	<i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Lung	PCR-RFLP	P-B case-control	Caucasians African Americans	331/687	Smoking
Matullo	2001	Italy	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Bladder	PCR-RFLP	H-B case-control	Caucasians	124/85	Smoking
Duan	2002	USA	<i>XRCC3</i> Cod.241	Skin	PCR-RFLP	H-B case control	Non-Hispanic whites	305/319	NULL
Seedhouse	2002	UK	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC1</i> Cod.194 <i>XRCC3</i> Cod.241 <i>NQO1</i> Cod. 187	Leukemia Secondary leukemia	PCR-RFLP	H-B case control	Caucasians	168/178	NULL
Shen	2002	USA	<i>XRCC3</i> Cod.241	Head and neck	PCR-SSCP	H-B case control	Non-Hispanic whites	367/354	Smoking Alcohol
Stern	2002b	USA	<i>XRCC3</i> Cod.241	Bladder	PCR-RFLP	H-B case-control	White or black	233/209	Smoking
Jacobsen	2003	Denmark	<i>XRCC3</i> Cod.241	Breast Skin	PCR-RFLP Sequencing	H-B case control	Caucasians	319/321 426/424	NULL
Medina	2003	USA	<i>XRCC3</i> Cod.241 <i>BRCA2</i> Cod. 372 <i>NBS1</i> Cod. 185	Lung	PCR-RFLP	Case-Only	Caucasians African-Americans	109	NULL
Misra	2003	Finland	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312 <i>XRCC3</i> Cod.241	Lung	TaqMan	P-B case control	Caucasians	315/315	Smoking

			<i>XRCC1</i> Cod.280 <i>APEX</i> Cod. 148						
Shen	2003	USA Italy	<i>XRCC1</i> Cod.399 <i>XPD/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Bladder	PCR-RFLP	H-B case control	Caucasians	201/214	Smoking
Smith	2003a	USA	<i>XRCC1</i> Cod.399 <i>XRCC1</i> Cod.194 <i>XRCC3</i> Cod.241	Breast	PCR-RFLP	P-B case control	Undefined	162/302	NULL
Smith	2003b	USA	<i>XRCC1</i> Cod.399 <i>XRCC1</i> Cod.194 <i>XRCC3</i> Cod.241 <i>XPF/ERCC4</i> Cod. 415	Breast	PCR-RFLP Sequencing	H-B case control	Undefined	253/268	NULL
Wang	2003	USA	<i>XRCC3</i> Cod.241	Lung	PCR-RFLP	P-B case control	African-Americans Mexican-Americans	112/190	Smoking
Benhamou	2004	France	<i>XRCC3</i> Cod.241 <i>XRCC2</i> Cod 188	Oral Pharynx Larynx	PCR-RFLP	H-B case control	Caucasians	250/172	Smoking
Bertram	2004	UK	<i>XRCC3</i> Cod.241	Skin	PCR-RFLP	P-B case control	Caucasians	140/335	NULL
Figueiredo	2004	Canada	<i>XRCC1</i> Cod.399 <i>XRCC3</i> Cod.241	Breast	Other	P-B case control	Undefined	402/402	Smoking Alcohol
Han	2004a	USA	<i>XRCC3</i> Cod.241 <i>XRCC3</i> 5' region pos.4541 <i>XRCC2</i> Cod 188 <i>XRCC3</i> IVS5-14 <i>LIG4</i> C299T <i>LIG4</i> Cod. 501	Breast	TaqMan	P-B case control	Undefined	1004/1385	NULL
Han	2004b	USA	<i>XRCC3</i> Cod.241 <i>XRCC2</i> Cod 188 <i>LIG4</i> C4062T <i>LIG4</i> C4044T <i>LIG4</i> Cod. 501 <i>XRCC2</i> C29244T <i>XRCC2</i> A31342G <i>XRCC2</i> G30833A <i>XRCC2</i> G30935A	Skin	TaqMan	P-B case control	Caucasians Asians Hispanics	805/873	NULL

			<i>XRCC3</i> A4552C						
			<i>XRCC3</i> Cod.241 <i>XRCC3</i> 5' region pos.4541 <i>XRCC2</i> Cod.188 <i>XRCC3</i> IVS5-14						
Han	2004c	USA		Endometrial	TaqMan	H-B case control	Undefined	220/666	NULL
			<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241						
Harms	2004	USA		Lung	PCR-RFLP	H-B case control	Caucasians	110/119	Smoking
			<i>XRCC3</i> Cod.241 <i>XRCC3</i> 5' region pos.4541 <i>XRCC3</i> IVS5-14 <i>XRCC3</i> IVS6 1571						
Jacobsen	2004	Denmark		Lung	TaqMan	Case-cohort	Caucasians	267/269	Smoking
			<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XPB/ERCC2</i> Cod.312 <i>XRCC3</i> Cod.241 <i>XPA</i> 5' NCR <i>APEX</i> Cod. 148						
Popanda	2004	Germany		Lung	PCR-RFLP	H-B case control	Caucasians	463/460	Smoking
			<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241 <i>CCND1</i> Cod.870 <i>XPB</i> Cod. 1104 <i>NQO1</i> Exon 6 <i>NBS1</i> Cod. 185 <i>XPC</i> exon 4 <i>MTHFR</i> exon 4 <i>MTHFR</i> exon 7 <i>NQO1</i> exon 4 <i>H-ras</i> exon 1 <i>GSTT1</i> Deletion allele		TaqMan PCR-RFLP				
Sanyal	2004	Sweden		Bladder		H-B case control	Caucasians	327/246	NULL
Shen	2004	China	<i>XRCC3</i> Cod.241	Gastric	PCR-RFLP	P-B case control	Asians	188/166	Smoking Alcohol
Wang	2004	USA	<i>XRCC1</i> Cod.399 <i>XRCC3</i> Cod.241	Glioma	PCR-RFLP	H-B case control	Caucasians	309/342	NULL

			<i>TP53</i> Cod.72 <i>RAD51</i> 5' UTR <i>XRCC7</i> G6721T						
Yeh	2005	Taiwan	<i>XRCC1</i> Cod.399 <i>XPB/ERCC2</i> Cod.751 <i>XRCC3</i> Cod.241	Colorectal	PCR-RFLP	H-B case control	Asians	727/736	NULL

Table 4. Results: *XPD/ERCC2*

Cod.156 Skin

		CA vs CC				AA vs CC				CA + AA vs CC			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Dybdahl 1999 Caucasians	3.26	0.66	16.07	1.51	5.33	0.78	36.37	1.04				
Fixed effects meta-analysis	Vogel 2001 Caucasians	2.01	0.98	4.13	7.43	1.67	0.69	4.04	4.92				
	Summary	2.18	1.13	4.20		2.05	0.92	4.56					
	<i>Heterogeneity test X=</i>	<i>0.29</i>				<i>1.16</i>							
	<i>p-value=</i>	<i>0.59</i>				<i>0.28</i>							
Crude OR	Dybdahl 1999 Caucasians	3.26	0.66	16.03	1.51	5.33	0.78	36.33	1.04	3.78	0.83	17.25	1.67
Fixed effects meta-analysis	Vogel 2001 Caucasians	2.01	0.98	4.14	7.39	1.67	0.69	4.04	4.92	1.90	0.96	3.76	8.28
	Winsey 2000 Caucasians	0.92	0.57	1.49	16.41	0.88	0.42	1.84	7.11	0.91	0.57	1.46	17.71
	Summary	1.26	0.86	1.85		1.30	0.77	2.21		1.26	0.87	1.81	
	<i>Heterogeneity test X=</i>	<i>4.59</i>				<i>3.45</i>				<i>5.24</i>			
	<i>p-value=</i>	<i>0.10</i>				<i>0.18</i>				<i>0.07</i>			

Cod.312 Breast

		GA vs GG				AA vs GG				GA + AA vs GG			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Justenhoven 2004 Caucasians					0.49	0.33	0.72	24.47				
Random effects meta-analysis	Shi 2004 Caucasians					2.06	0.63	6.71	2.75	2.01	1.03	3.93	8.54
	Tang 2002 Undefined									1.58	0.85	2.94	9.92
	Summary					0.89	0.22	3.63		1.77	1.12	2.79	
	<i>Heterogeneity test X=</i>					<i>5.17</i>				<i>0.27</i>			
	<i>p-value=</i>					<i>0.02</i>				<i>0.61</i>			
Crude OR	Justenhoven 2004 Caucasians	0.54	0.42	0.70	62.00	0.45	0.30	0.67	24.14	0.52	0.41	0.66	71.18
Random effects meta-analysis	Shi 2004 Caucasians	1.88	0.94	3.75	8.03	2.11	0.67	6.72	2.87	1.92	1.00	3.70	8.97
	Tang 2002 Undefined	1.58	0.85	2.93	9.93	1.00	0.36	2.79	3.63	1.42	0.80	2.52	11.71
	Summary	1.12	0.46	2.74		0.87	0.34	2.23		1.08	0.44	2.65	
	<i>Heterogeneity test X=</i>	<i>18.29</i>				<i>7.39</i>				<i>21.01</i>			
	<i>p-value=</i>	<i><0.01</i>				<i>0.02</i>				<i><0.01</i>			

Cod.312 Lung

		GA vs GG				AA vs GG				GA + AA vs GG			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights

Adjusted OR	Liang 2003 Asians	1.03	0.80	1.32	61.82	10.33	1.29	82.61	0.89
Fixed effects meta-analysis	Misra 2003 Caucasians	0.72	0.50	1.04	28.65	0.93	0.55	1.58	13.80
	Popanda 2004 Undefined	1.14	0.83	1.56	39.39	1.05	0.68	1.62	20.69
	Spitz 2001 Caucasians	0.93	0.63	1.38	24.54	1.51	0.76	3.00	8.15
	Zhou 2002 Caucasians	0.98	0.80	1.20	93.47	1.41	1.10	1.80	63.36
	Butkiewicz 2001 Caucasians					0.72	0.32	1.64	5.68
	Summary	0.98	0.86	1.11		1.25	1.04	1.51	
	<i>Heterogeneity test X=</i>	<i>3.84</i>				<i>8.74</i>			
	<i>p-value=</i>	<i>0.43</i>				<i>0.12</i>			

Crude OR	Butkiewicz 2001 Caucasians	0.50	0.26	0.94	9.47	0.74	0.33	1.66	5.85	0.56	0.31	1.01	11.04
Fixed effects meta-analysis	Liang 2003 Asians	0.98	0.76	1.28	55.66	11.24	1.45	87.25	0.91	1.06	0.82	1.37	57.93
	Misra 2003 Caucasians	0.74	0.53	1.04	33.87	0.93	0.57	1.52	16.14	0.78	0.57	1.07	38.45
	Popanda 2004 Undefined	1.15	0.87	1.52	48.90	1.07	0.72	1.58	25.19	1.13	0.87	1.46	55.56
	Spitz 2001 Caucasians	0.92	0.67	1.25	38.92	1.57	0.91	2.72	12.83	1.01	0.75	1.36	43.68
	Zhou 2002 Caucasians	1.00	0.84	1.19	127.42	1.47	1.12	1.92	53.73	1.08	0.92	1.28	142.23
	Summary	0.96	0.86	1.07		1.30	1.08	1.55		1.02	0.92	1.13	
	<i>Heterogeneity test X=</i>	<i>8.26</i>				<i>10.13</i>				<i>7.87</i>			
	<i>p-value=</i>	<i>0.14</i>				<i>0.07</i>				<i>0.16</i>			

Cod.312 Skin

		GA vs GG				AA vs GG				GA + AA vs GG			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Baccarelli 2004 Caucasians									1.50	0.90	2.50	14.72
	Vogel 2001 Caucasians									1.05	0.57	1.94	10.24
	Summary									1.30	0.88	1.92	
	<i>Heterogeneity test X=</i>									<i>0.77</i>			
	<i>p-value=</i>									<i>0.38</i>			
Crude OR	Baccarelli 2004 Caucasians	1.20	0.75	1.92	17.23	0.85	0.42	1.74	7.50	1.12	0.71	1.77	18.53
	Vogel 2001 Caucasians	1.02	0.51	2.02	8.21	1.11	0.49	2.54	5.63	1.05	0.57	1.94	10.12
	Winsey 2000 Caucasians	1.03	0.64	1.67	16.48	1.48	0.76	2.87	8.76	1.13	0.72	1.78	18.87
	Summary	1.09	0.81	1.48		1.13	0.75	1.72		1.11	0.84	1.48	
	<i>Heterogeneity test X=</i>	<i>0.24</i>				<i>1.24</i>				<i>0.04</i>			
	<i>p-value=</i>	<i>0.89</i>				<i>0.54</i>				<i>0.98</i>			

Cod.751 Bladder

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Sanyal 2004 Caucasians	1.07	0.73	1.57	26.20	1.31	0.77	2.22	13.71				

Fixed effects meta-analysis	Shen 2003 Caucasians	0.89	0.58	1.36	21.16	1.00	0.57	1.75	12.21	0.92	0.62	1.37	24.45
	Stern 2002b Caucasians	1.10	0.73	1.66	22.49	0.80	0.41	1.55	8.80				
	Matullo 2001 Caucasians									0.71	0.32	1.58	6.03
	Summary	1.02	0.81	1.29		1.05	0.75	1.47		0.87	0.61	1.25	
	<i>Heterogeneity test X=</i>	<i>0.58</i>				<i>1.35</i>				<i>0.32</i>			
	<i>p-value=</i>	<i>0.75</i>				<i>0.51</i>				<i>0.57</i>			
Crude OR	Matullo 2001 Caucasians	0.76	0.40	1.43	9.40	0.75	0.31	1.77	5.14	0.75	0.41	1.39	10.17
Fixed effects meta-analysis	Sanyal 2004 Caucasians	1.08	0.75	1.56	28.27	1.29	0.78	2.12	15.47	1.13	0.80	1.60	32.06
	Shen 2003 Caucasians	0.89	0.58	1.36	21.14	1.01	0.58	1.77	12.34	0.92	0.62	1.37	24.31
	Stern 2002b Caucasians	1.05	0.69	1.59	21.79	0.85	0.46	1.55	10.53	1.00	0.67	1.48	24.45
	Summary	0.98	0.78	1.21		1.02	0.76	1.37		0.99	0.80	1.21	
	<i>Heterogeneity test X=</i>	<i>1.19</i>				<i>1.70</i>				<i>1.44</i>			
	<i>p-value=</i>	<i>0.76</i>				<i>0.64</i>				<i>0.70</i>			

Cod.751 Breast

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Justenhoven 2004 Caucasians	1.09	0.85	1.39	63.53	1.32	0.94	1.86	32.99				
Fixed effects meta-analysis	Shi 2004 Caucasians	1.41	0.71	2.82	8.00	1.49	0.46	4.84	2.76	1.19	0.62	2.30	8.82
	Tang 2002 Undefined	1.03	0.58	1.84	11.32	1.02	0.45	2.30	5.80				
	Terry 2005 Undefined	1.22	1.01	1.47	113.17	1.18	0.91	1.53	56.92	1.21	1.01	1.44	122.14
	Summary	1.17	1.02	1.35		1.22	1.00	1.49		1.21	1.02	1.43	
	<i>Heterogeneity test X=</i>	<i>0.98</i>				<i>0.56</i>				<i><0.01</i>			
	<i>p-value=</i>	<i>0.81</i>				<i>0.90</i>				<i>0.96</i>			
Crude OR	Justenhoven 2004 Caucasians	1.08	0.85	1.38	64.43	1.32	0.94	1.84	34.03	1.14	0.90	1.43	73.22
Fixed effects meta-analysis	Shi 2004 Caucasians	1.12	0.57	2.22	8.30	1.69	0.53	5.40	2.85	1.20	0.63	2.31	9.12
	Tang 2002 Undefined	1.10	0.62	1.95	11.59	0.91	0.43	1.96	6.63	1.04	0.61	1.76	13.72
	Terry 2005 Undefined	1.20	1.00	1.44	114.39	1.18	0.91	1.54	55.73	1.20	1.01	1.42	127.76
	Summary	1.15	1.00	1.32		1.22	1.00	1.48		1.17	1.02	1.33	
	<i>Heterogeneity test X=</i>	<i>0.50</i>				<i>1.10</i>				<i>0.33</i>			
	<i>p-value=</i>	<i>0.92</i>				<i>0.78</i>				<i>0.95</i>			

Cod.751 Esophageal Squamous cell carcinoma

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights

Crude OR	Xing 2002a Asians	1.11	0.77	1.60	28.49	1.23	0.25	6.12	1.49	1.11	0.77	1.59	29.59
Fixed effects meta-analysis	Yu 2004 Asians	1.09	0.52	2.28	7.03	7.39	1.62	33.73	1.67	1.75	0.92	3.32	9.39
	Summary	1.10	0.79	1.53		3.62	1.30	10.06		1.24	0.91	1.70	
	<i>Heterogeneity test X=</i>	<0.01				2.59				1.47			
	<i>p-value=</i>	0.97				0.11				0.23			

Cod.751 Leukemia

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Allan 2004 Caucasians	1.20	0.91	1.58	51.66	1.22	0.84	1.78	27.25				
Fixed effects meta-analysis	Seedhouse 2002 Caucasians	0.74	0.31	1.77	5.06	0.61	0.18	2.05	2.61				
	Summary	1.15	0.89	1.49		1.15	0.80	1.64					
	<i>Heterogeneity test X=</i>	1.08				1.14							
	<i>p-value=</i>	0.30				0.28							
Crude OR	Allan 2004 Caucasians	1.18	0.91	1.53	55.88	1.18	0.82	1.68	29.75	1.18	0.92	1.51	63.56
Fixed effects meta-analysis	Seedhouse 2002 Caucasians	1.20	0.63	2.28	9.16	1.09	0.44	2.69	4.72	1.17	0.64	2.15	10.36
	Summary	1.18	0.93	1.51		1.16	0.83	1.62		1.18	0.94	1.48	
	<i>Heterogeneity test X=</i>	<0.01				0.02				<0.01			
	<i>p-value=</i>	0.97				0.88				0.98			

Cod.751 Lung

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	David-Beabes 2001 African-Americans	1.08	0.66	1.76	15.97	1.03	0.40	2.65	4.30	1.07	0.67	1.71	17.50
Fixed effects meta-analysis	David-Beabes 2001 Caucasians	0.97	0.62	1.52	19.11	1.34	0.74	2.42	10.95	1.06	0.70	1.61	22.15
	Harms 2004 Caucasians	1.39	0.79	2.44	12.08	0.95	0.26	3.45	2.31	1.33	0.77	2.30	12.73
	Liang 2003 Asians	0.95	0.74	1.22	61.48	2.71	1.01	7.26	3.96				
	Misra 2003 Caucasians	0.82	0.56	1.20	27.05	1.02	0.61	1.70	14.63	0.87	0.61	1.24	31.24
	Popanda 2004 Undefined	1.16	0.85	1.59	39.18	1.39	0.90	2.14	20.48				
	Spitz 2001 Caucasians	1.07	0.78	1.47	38.26	1.36	0.84	2.20	16.58				
	Zhou 2002 Caucasians	1.01	0.87	1.17	185.67	1.17	0.91	1.51	58.89				
	Xing 2002b Asians									1.42	0.94	2.15	22.45
	Summary	1.02	0.92	1.12		1.24	1.05	1.47		1.09	0.91	1.32	
	<i>Heterogeneity test X=</i>	3.60				3.96				3.68			
	<i>p-value=</i>	0.82				0.78				0.45			

Crude OR	David-Beabes 2001 African-Americans	1.14	0.74	1.74	21.18	1.39	0.59	3.26	5.31	1.17	0.78	1.76	23.00
Fixed effects meta-analysis	David-Beabes 2001 Caucasians	1.14	0.78	1.68	26.29	1.72	1.04	2.86	15.00	1.27	0.89	1.82	30.38
	Harms 2004 Caucasians	1.32	0.77	2.24	13.48	1.05	0.33	3.31	2.89	1.28	0.76	2.16	14.28
	Liang 2003 Asians	0.93	0.73	1.19	66.60	2.34	0.89	6.11	4.16	0.98	0.78	1.24	70.16
	Misra 2003 Caucasians	0.87	0.62	1.23	32.09	1.09	0.68	1.74	17.24	0.92	0.66	1.28	35.77
	Popanda 2004 Undefined	1.14	0.86	1.51	48.39	1.36	0.92	2.01	25.37	1.19	0.91	1.55	54.78
	Spitz 2001 Caucasians	1.07	0.78	1.46	38.33	1.36	0.84	2.20	16.58	1.12	0.83	1.51	42.81
	Xing 2002b Asians	1.33	0.88	2.01	22.51	1.91	0.45	8.06	1.85	1.37	0.91	2.04	23.90
	Zhou 2002 Caucasians	1.03	0.86	1.22	123.31	1.19	0.92	1.53	59.98	1.06	0.90	1.25	138.25
	Summary	1.05	0.95	1.16		1.31	1.11	1.54		1.10	1.00	1.21	
	<i>Heterogeneity test X=</i>	<i>4.72</i>				<i>4.20</i>				<i>4.78</i>			
	<i>p-value=</i>	<i>0.86</i>				<i>0.84</i>				<i>0.85</i>			

Cod.751 Skin

		CA vs AA				CC vs AA				CA + CC vs AA			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR	Baccarelli 2004 Caucasians									1.30	0.67	2.54	8.59
Random effects meta-analysis	Dybdahl 1999 Caucasians					0.23	0.04	1.26	1.33				
	Vogel 2001 Caucasians					1.83	0.71	4.70	4.31	1.18	0.64	2.18	10.15
	Summary					0.74	0.10	5.51		1.23	0.78	1.94	
	<i>Heterogeneity test X=</i>					<i>4.35</i>				<i>0.04</i>			
	<i>p-value=</i>					<i>0.04</i>				<i>0.83</i>			
Crude OR	Baccarelli 2004 Caucasians	1.12	0.71	1.79	17.67	0.74	0.39	1.40	9.42	1.02	0.65	1.58	19.55
Fixed effects meta-analysis	Dybdahl 1999 Caucasians	0.90	0.24	3.41	2.17	0.20	0.02	2.16	0.68	0.67	0.19	2.33	2.45
	Vogel 2001 Caucasians	1.05	0.55	2.01	9.14	1.83	0.71	4.70	4.33	1.18	0.64	2.19	10.06
	Winsey 2000 Caucasians	0.75	0.46	1.22	16.00	1.13	0.59	2.14	9.29	0.84	0.53	1.32	18.29
	Summary	0.95	0.71	1.27		0.98	0.66	1.45		0.96	0.73	1.26	
	<i>Heterogeneity test X=</i>	<i>1.50</i>				<i>4.33</i>				<i>1.17</i>			
	<i>p-value=</i>	<i>0.68</i>				<i>0.23</i>				<i>0.76</i>			

Table 5. Results: XRCC3

Cod.241 Bladder

		CT vs CC				TT vs CC				CT + TT vs CC			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR fixed effects meta-analysis	Sanyal 2004 Caucasians	0.97	0.66	1.42	26.67	1.31	0.75	2.27	12.64				
	Shen 2003 Caucasians	0.60	0.40	0.90	22.74	0.74	0.39	1.39	9.62	0.63	0.42	0.94	24.32
	Stern 2002b Mixed	1.20	0.78	1.85	20.54	1.50	0.82	2.76	10.39				
	Matullo 2001 Caucasians									2.72	1.37	5.42	8.10
	Summary	0.88	0.70	1.12		1.16	0.82	1.63		1.27	0.30	5.33	
<i>Heterogeneity test X=</i>		5.56				2.82				13.00			
<i>p-value=</i>		0.06				0.24				<0.01			
Crude OR Random effects meta-analysis	Matullo 2001 Caucasians	3.50	1.81	6.75	8.90	1.77	0.85	3.71	7.04	2.71	1.51	4.87	11.26
	Sanyal 2004 Caucasians	0.93	0.64	1.33	29.37	1.42	0.85	2.38	14.51	1.03	0.74	1.45	33.76
	Shen 2003 Caucasians	0.60	0.39	0.91	21.88	0.69	0.37	1.30	9.72	0.62	0.41	0.92	24.11
	Stern 2002b Mixed	1.24	0.83	1.84	24.05	1.48	0.81	2.72	10.48	1.28	0.88	1.88	26.80
	Summary	1.19	0.66	2.12		1.26	0.93	1.70		1.18	0.71	1.95	
<i>Heterogeneity test X=</i>		20.91				4.81				18.02			
<i>p-value=</i>		<0.01				0.19				<0.01			

Cod.241 Breast

		CT vs CC				TT vs CC				CT + TT vs CC			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR fixed effects meta-analysis	Figueiredo 2004 Undefined	0.96	0.70	1.31	39.96	1.44	0.94	2.20	21.48				
	Han 2004a Undefined	0.87	0.72	1.05	107.95	0.98	0.75	1.28	53.78				
	Jacobsen 2003 Caucasians	1.01	0.75	1.36	44.48	0.89	0.59	1.35	22.43				
	Summary	0.92	0.80	1.06		1.04	0.86	1.27					
<i>Heterogeneity test X=</i>		0.80				3.01							
<i>p-value=</i>		0.67				0.22							
Crude OR Fixed effects meta-analysis	Figueiredo 2004 Undefined	0.98	0.72	1.33	40.95	1.44	0.95	2.19	22.28	1.08	0.81	1.44	45.97
	Han 2004a Undefined	0.85	0.71	1.02	115.55	1.00	0.76	1.30	54.44	0.88	0.74	1.05	128.93
	Jacobsen 2003 Caucasians	1.01	0.75	1.35	44.72	0.89	0.59	1.35	22.36	0.98	0.74	1.29	49.99
	Smith 2003b Caucasians	0.88	0.60	1.29	26.80	1.84	1.08	3.13	13.70	1.06	0.75	1.52	30.55
	Smith 2003a Mixed	0.95	0.62	1.44	21.90	0.96	0.54	1.69	11.92	0.95	0.64	1.41	24.80
Summary		0.91	0.80	1.03		1.11	0.94	1.33		0.95	0.85	1.07	
<i>Heterogeneity test X=</i>		1.24				7.04				1.89			
<i>p-value=</i>		0.87				0.13				0.76			

Cod.241 Lung

		CT vs CC				TT vs CC				CT + TT vs CC			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Adjusted OR fixed effects meta-analysis	David-Beabes 2001 African-Americans	0.90	0.55	1.48	15.68	1.67	0.57	4.88	3.34	0.98	0.61	1.57	17.43
	David-Beabes 2001 Caucasians	0.93	0.60	1.44	20.37	0.94	0.50	1.75	9.92	0.93	0.62	1.40	22.76
	Harms 2004 Caucasians	0.66	0.36	1.19	10.90	1.25	0.47	3.32	4.02	0.75	0.43	1.30	12.55
	Jacobsen 2004 Caucasians	1.54	1.05	2.26	26.15	1.46	0.87	2.46	14.11				
	Misra 2003 Caucasians	0.96	0.69	1.34	34.88	1.12	0.59	2.12	9.39	1.14	0.62	2.11	10.17
	Popanda 2004 Undefined	0.95	0.69	1.31	37.39	1.29	0.85	1.97	21.49				
	Summary	1.00	0.85	1.18		1.25	0.97	1.60		0.93	0.73	1.20	
	<i>Heterogeneity test X=</i>	7.19				1.56				1.05			
	<i>p-value=</i>	0.21				0.91				0.79			
Crude OR Fixed effects meta-analysis	David-Beabes 2001 African-Americans	0.93	0.60	1.43	20.68	1.36	0.53	3.48	4.36	0.97	0.64	1.47	22.45
	David-Beabes 2001 Caucasians	0.86	0.59	1.24	27.43	0.81	0.47	1.39	13.29	0.84	0.59	1.20	30.99
	Harms 2004 Caucasians	0.76	0.43	1.32	12.47	1.20	0.48	2.98	4.63	0.83	0.49	1.40	14.26
	Jacobsen 2004 Caucasians	1.29	0.89	1.88	27.51	1.05	0.63	1.76	14.5	1.51	1.06	2.16	30.10
	Misra 2003 Caucasians	0.87	0.63	1.20	35.93	1.22	0.67	2.22	10.65	0.91	0.67	1.25	39.36
	Popanda 2004 Undefined	0.87	0.65	1.16	47.36	1.23	0.84	1.80	26.72	0.96	0.73	1.25	54.06
	Summary	0.92	0.79	1.07		1.11	0.88	1.39		0.99	0.86	1.14	
	<i>Heterogeneity test X=</i>	4.12				1.92				6.94			
	<i>p-value=</i>	0.53				0.86				0.23			

Cod.241 Skin

		CT vs CC				TT vs CC				CT + TT vs CC			
		OR	0.95	CI	weights	OR	0.95	CI	weights	OR	0.95	CI	weights
Crude OR Random effects meta-analysis	Bertram 2004 Caucasians	1.12	0.72	1.72	20.58	1.47	0.80	2.72	10.21	1.19	0.79	1.79	22.90
	Duan 2002 Caucasians	0.91	0.65	1.28	33.21	0.82	0.50	1.36	15.25	0.89	0.65	1.23	36.59
	Winsey 2000 Caucasians	2.35	1.44	3.84	15.89	2.58	1.28	5.16	7.95	2.40	1.51	3.82	17.77
	Summary	1.31	0.77	2.23		1.41	0.74	2.71		1.34	0.77	2.33	
	<i>Heterogeneity test X=</i>	9.77				7.06				11.73			
	<i>p-value=</i>	0.01				0.03				<0.01			